Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.

• Material Type: 博士論文
• Title: Ex Vivo Expanded and Activated Natural Killer Cells Prolong the Overall Survival of Mice with Glioblastoma-like Cell-Derived Tumors.
• Author/Editor: Shida, Yoichi; Nakazawa, Tsutomu; Matsuda, Ryosuke; Morimoto, Takayuki; Nishimura, Fumihiko; Nakamura, Mitsutoshi; Maeoka, Ryosuke; Yamada, Shuichi; Nakagawa, Ichiro; Park, Young-Soo; Yasukawa, Motoaki; Tojo, Takashi; Tsujimura, Takahiro; Nakase, Hiroyuki
• Author Heading: Shida, Yoichi; Nakazawa, Tsutomu; Matsuda, Ryosuke; Morimoto, Takayuki; Nishimura, Fumihiko; Nakamura, Mitsutoshi; Maeoka, Ryosuke; Yamada, Shuichi; Nakagawa, Ichiro; Park, Young-Soo; Yasukawa, Motoaki; Tojo, Takashi; Tsujimura, Takahiro; Nakase, Hiroyuki
• Publication, Distribution, etc.: MDPI
• Publication Date: 2021-09-15
• Publication Date (W3CDTF): 2021-09-15
• Alternative Title: 細胞外増幅活性Natural Killer細胞は膠芽腫由来腫瘍を移植したマウスの全生存期間を延長させる
• Periodical title: International journal of molecular sciences
• No. or year of volume/issue: 22 18
• Volume: 22
• Issue: 18
• Pages: Article No.9975-
• ISSN (Periodical Title): ISSN : 1422-0067
• Degree grantor/type: 奈良県立医科大学
• Date Granted: 2022-03-15
• Dissertation Number: 甲第827号
• Degree Type: 博士（医学）
• Text Language Code: eng
• Subject Heading: PD-1; PD-L1; NK cell; glioblastoma
• Target Audience: 一般
• Note (General): type:Thesis; Glioblastoma (GBM) is the leading malignant intracranial tumor and is associated with a poor prognosis. Highly purified, activated natural killer (NK) cells, designated as genuine induced NK cells (GiNKs), represent a promising immunotherapy for GBM. We evaluated the anti-tumor effect of GiNKs in association with the programmed death 1(PD-1)/PD-ligand 1 (PD-L1) immune checkpoint pathway. We determined the level of PD-1 expression, a receptor known to down-regulate the immune response against malignancy, on GiNKs. PD-L1 expression on glioma cell lines (GBM-like cell line U87MG, and GBM cell line T98G) was also determined. To evaluate the anti-tumor activity of GiNKs in vivo, we used a xenograft model of subcutaneously implanted U87MG cells in immunocompromised NOG mice. The GiNKs expressed very low levels of PD-1. Although PD-L1 was expressed on U87MG and T98G cells, the expression levels were highly variable. Our xenograft model revealed that the retro-orbital administration of GiNKs and interleukin-2 (IL-2) prolonged the survival of NOG mice bearing subcutaneous U87MG-derived tumors. PD-1 blocking antibodies did not have an additive effect with GiNKs for prolonging survival. GiNKs may represent a promising cell-based immunotherapy for patients with GBM and are minimally affected by the PD-1/PD-L1 immune evasion axis in GBM.; 博士（医学）・甲第827号・令和4年3月15日; © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).; identifier:International journal of molecular sciences Vol.22 No.18 Article No.9975 (2021 Sep); identifier:14220067; identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/4010; identifier:International journal of molecular sciences, 22(18): Article No.9975
• Access Restrictions: インターネット公開
• Related Material (DOI): 10.3390/ijms22189975
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 奈良県立医科大学 : 奈良県立医科大学機関リポジトリ GINMU

Table of Contents

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/4010/1/01%e7%94%b2827%e6%9c%ac%e6%96%87%e3%81%ae%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/4010/2/02%e7%94%b2827%e5%af%a9%e6%9f%bb%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/4010/3/03%e7%94%b2827%e6%9c%ac%e6%96%87.pdf fulltext